<DOC>
	<DOCNO>NCT00740103</DOCNO>
	<brief_summary>CNI-1493-CD05 open-label extension study CNI-1493-CD04 . In CD05 study , patient eligible 5 course semapimod 60 mg IV x 3 day every 6 - 8 week . Primary objective assessment efficacy cumulative dos semapimod measure decrease Crohn 's Disease Activity Index ( CDAI ) .</brief_summary>
	<brief_title>Long-term Study Semapimod ( CNI-1493 ) Treatment Crohn 's Disease</brief_title>
	<detailed_description>CNI-1493-CD05 open-label extension study CNI-1493-CD04 . In CD05 study , patient eligible 5 course semapimod 60 mg IV x 3 day every 6 - 8 week . Primary objective assessment efficacy cumulative dos semapimod measure decrease Crohn 's Disease Activity Index ( CDAI ) . In addition , safety repeat course measure record adverse event time .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Semapimod</mesh_term>
	<criteria>Inclusion Criteria 1 . Patients satisfactorily complete study CNI149304 eligible participation study . Satisfactory completion define follow : 1 . The patient meet eligibility criterion participation study CNI149304 grant exemption medical monitor factor indicate ineligibility . 2 . The patient receive least 2 3 plan dos study medication . 3 . The patient adverse event &gt; grade 2 felt possibly , probably definitely relate study medication . 4 . The patient underwent require evaluation , safety efficacy , baseline day 29 , patient enrol day 43 57 study CNI1493CD04 , least one full later evaluation , ie procedure require day 43 and/or 57 . 2 . At baseline study CNI1493CD05 , patient meet concomitant medication criterion study CNI1493CD04 : 1 . Patients receive medication CD medication least 8 week prior screen stable dos least 2 week prior baseline assessment , follow exception : methotrexate stable dose least 4 week must receive 25mg/week azathioprine 6mercaptopurine stable dose least 10 week corticosteroid least 2 week stable 2 week . They receive 20 mg/day prednisone ( equivalent ) . mesalazine least 6 week stable dose least 2 week antibiotics CD least 2 week stable dose 2 week 2 . Patients use CD medication stop previous use agent least 4 week prior baseline assessment study CNI1493CD05 . 3 . Patients required sign inform consent specifically study , addition consent study CNI1493CD04 . 4 . Men woman childbearing potential use barrier method ( diaphragm condom ) contraception continue least 3 month last study medication . It strongly recommend two form use . 5 . Patients able adhere study visit schedule and/or protocol requirement . Only patient complete CD04 eligible must meet exclusion criterion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Semapimod</keyword>
	<keyword>Crohn 's Disease</keyword>
	<keyword>TNF-alpha inhibitor</keyword>
	<keyword>MAP Kinase inhibitor</keyword>
	<keyword>CNI-1493</keyword>
</DOC>